Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs IAC/Interactivecorp (PPLI) Price & Performance

ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.

Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.

PPLI trades at $46.50, down 2.13% on the day, near its 52-week high. The stock shows bullish technical signals with strong moving average support, though RSI levels suggest overbought conditions. Fundamentally, revenue has declined from $5.2B in 2022 to $2.4B in 2025, with recent quarters missing EPS expectations. The company maintains a high gross margin of 66.49% but struggles with profitability, posting a net loss of $104M in 2025. Analyst consensus remains bullish with a $55.40 price target, while recent news questions valuation after a 3.6% rally.

PPLI presents a mixed outlook with bullish analyst sentiment against challenging fundamentals. The 63.64% buy rating and 25% upside to consensus target reflect optimism for a turnaround, but consecutive earnings misses and negative cash flow pose significant execution risks. Investors face volatility from inconsistent profitability despite attractive valuation metrics like P/B of 0.76. The key catalyst remains demonstrating sustainable earnings growth amid declining revenues.